Abstract T MP1: Predictive Factors of Favorable Outcome in Patients With Acute Large Vessel Occlusion
Background: The data of the nationwide prospective registry of acute cerebral large vessel occlusion (RESCUE-Japan Registry) was analyzed to know the predictive factors of favorable outcome at 90 days
Methods: In this registry, patients with acute cerebral large vessel occlusion admitted within 24 h after onset were prospectively registered. The effect of various factors including endovascular treatment (EVT), intravenous tissue plasminogen activator (IV-tPA), and other medication on favorable outcome (modified Rankin scale 0-2) was analyzed.
Results: A total of 1,315 patients were analyzed. The number of patients in favorable outcome was 422 (32.1%). Logistic regression analysis revealed that higher NIHSS (OR 0.875, 95%CI 0.858-0.894) and advanced age (OR 0.963, 95% CI 0.952-0.975) were significantly related to unfavorable outcome (Fig. 1). In contrast, IV-tPA (OR 2.489, 95% CI 1.867-3.319), EVT (OR 1.375, 95% CI 1.013-1.865), and free radical scavenger, edaravon, (OR 1.483, 95% CI 1.027-2.143) were significantly associated with favorable outcome. Combination with IV-tPA or EVT with free radical scavenger was better than without it (Fig. 2).
Conclusions: This analysis indicated that IV-tPA, EVT and free radical scavenger were effective to obtain favorable outcome in the patients with acute large vessel occlusion. Combination with free radical scavenger was also effective.
- Acute stroke care
- Endovascular stroke treatment
- Free radicals/Free-radical scavengers
- Cerebrovascular disorders
Author Disclosures: S. Yoshimura: Speakers' Bureau; Significant; Sanofi Pharmaceutical Co., Otsuka Pharmaceutical Co.. Consultant/Advisory Board; Modest; Terumo. N. Sakai: Speakers' Bureau; Significant; Otsuka Pharmaceurical Co.. Consultant/Advisory Board; Modest; Asahi Intech, Terumo, Codman, Covidien, Stryker, Medtronic. Y. Okada: None. K. Kitagawa: Speakers' Bureau; Significant; Sanofi Pharamaceutical Co. K. Kimura: Speakers' Bureau; Significant; Otsuka Pharamaceutical Co., Tanabemitsubishi Pharamaceutical Co., Boehringer Ingelheim Pharamaceutical Co. N. Tanahashi: Speakers' Bureau; Significant; Daiichi-Sankyo Pharamaceutical Co.,, Sanofi Pharamaceutical Co.,, Bayer Pharamaceutical Co.,, Tanabe-Mitsubishi Pharamaceutical Co. H. Yamagami: Research Grant; Significant; Japan Cardiovascular Research Foundation. Speakers' Bureau; Modest; Otsuka Pharmaceutical Co., Nippon Boehringer Ingelheim Co.. Y. Egashira: None. T. Hyogo: None.
- © 2014 by American Heart Association, Inc.